News

With Open Payments it is possible for Pfizer to better understand its own investigator usage pattern and how that pattern may differ from the practices of other pharmaceutical companies.

In this interview, Kevin Hudziak will expand on Lilly’s initiatives to change the face of clinical trials through patient engagement and education initiatives.

Digital media is becoming a crucial vehicle for finding “Patient X” for rare disease drug trials. Three areas in particular where digital media is helping with the detective work are explored.

Rare disease interests in Europe add more voices to push for greater backing of research incentives, infrastructure.

The ability to diagnose cancer at earlier stages of the disease is constrained by the specificity and mechanics of traditional diagnostic methods. The growing use of liquid biopsy technology may help overcome such barriers and potentially revolutionize cancer research, patient treatment, and survivor care.

Safeguarding trials from CRO turnover. How to ensure commitment of qualified resources through thick and thin.

Click the title above to open the Applied Clinical Trials March 2018 issue in an interactive PDF format.

The rare disease community in Europe has come out fighting to defend its record-and its future-in the face of what it sees as growing threats to research.

By leveraging EHR data, the industry can transform how it conducts clinical research and delivers health care in the future.

With Open Payments US investigator names and experience will become public knowledge.

Numerous factors can adversely impact study startup and its efficiency, in an industry plagued by rising development costs and increasing complexities.

Updated employee announcements, business news, awards, and recognition in the industry today.

Outlining the growing attention and pursuits around social media in adverse event reporting and advancing patient-centric initiatives in clinical trials.